Key clinical point: Reductions in hepatic venous pressure reduced the risk of adverse events, liver transplant, and deaths in adults with cirrhosis with and without ascites.

Major finding: Of 661 patients without ascites and 452 with ascites, responders to pressure reduction had significantly lower odds of death or liver transplantation compared with nonresponders (OR, 0.50, and OR, 0.47, respectively).

Study details: The data come from a meta-analysis of 15 studies that included 1,113 cirrhosis patients.

Disclosures: The study was supported by multiple sources including the University of Modena and Reggio Emilia, Yale Liver Center, National Institutes of Health, and Instituto de Salud Carlos III, and was cofunded by the European Union. The researchers had no financial conflicts to disclose.